Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Abstract
The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients with relapsed or refractory acute lymphoblastic leukemia than does standard...
Paper Details
Title
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Published Date
Aug 25, 2016
Volume
375
Issue
8
Pages
740 - 753
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History